21 Jul 2026
Fact.MR reports that the global chromosomal phasing NIPT market will expand from $639.6Mn in 2026 to $1.27Bn by 2036, a 7.1% CAGR. That represents an absolute dollar opportunity of $630.4Mn. Chromosomal phasing NIPT is becoming more focused on showing how genetic changes pass from parents to a baby, giving doctors clearer information for prenatal counselling than a simple positive or negative result.
Laboratories and hospital genetics departments are expected to prefer tests that clearly state the minimum fetal DNA level needed and whether parental samples are required, rather than broad panel claims. Test developers must publish how chromosome mixing is handled and set clear rules for failed or unclear results, so doctors and insurance reviewers are not left to draw their own conclusions from an ambiguous report.
Single-gene NIPT leads test-type demand at about 30%, focusing on a known inherited condition already flagged by carrier screening or family history. Parental haplotyping tops technology demand at roughly 30% by showing which genetic change may pass from each parent to the baby, and monogenic disorders lead the indication split at close to 30%, ahead of chromosomal abnormalities. Hospitals place about 30% of end-user demand, bringing prenatal doctors, laboratory services, and counselling together.
Germany leads at a 9.6% CAGR through 2036 on university-hospital genetics capacity, with Brazil close behind at 8.9% as private laboratories expand inherited-risk testing. The United States follows at 8.2% on commercial test development and prospective validation, ahead of South Korea (7.5%), the United Kingdom (6.7%), and Japan (6.0%).
The need for confirmatory invasive diagnosis is the main brake, since a high-risk screening result often has to be checked with chorionic villus sampling or amniocentesis before doctors change care, and use may stay limited where that access is not easy. Fetal-fraction limits add a second constraint, as some samples contain too little fetal DNA for a clear result, requiring laboratories to set firm rules for failed tests.
Natera and BillionToOne lead the closest commercial work, with Natera competing through SNP-based and LinkedSNP prenatal tests and BillionToOne offering UNITY testing through its molecular counting platform. Illumina supports laboratories with sequencing systems and NIPT tools, while Roche and BGI Genomics add broader laboratory reach. Competition depends on result reliability and the counselling support available after a high-risk result.
Clearly show when a chromosomal phasing result is only a screening result, and state when chorionic villus sampling or amniotic fluid testing is required for confirmation. Build enough counselling support before offering more single-gene NIPT options to families with a known inherited-disease history, and avoid broad claims about large test panels, since insurance approval often depends on one clear medical question and a stated next step.
Beyond the headline forecast, the Fact.MR study segments demand by test type, technology, indication, and end user. The study also compares country-level growth across North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East amp Africa from 2026 to 2036. For related analysis, see Fact.MR39s coverage of chromosomal aberration testing and dengue testing.
Expert analysis, actionable insights, and strategic recommendations of the highly seasoned healthcare team at Fact.MR helps clients from across the globe with their unique business intelligence needs. With a repertoire of over a thousand reports and 1 million-plus data points, the team has analyzed the healthcare industry across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.
For more information, refer to our market research report or contact the PR author.
Chromosomal Phasing Non-Invasive Prenatal Testing Market
Free SampleAbout Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. We are known for our syndicated research, custom research, and consulting solutions.